Advanced Glycation End Products, Diabetes, and Bone Strength

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
type 1 diabetes mellitus 1 endocrinologydiseases
type 2 diabetes mellitus 3 endocrinologydiseases
Teriparatide 2 endocrinologydiseasesdrugs
diabetes mellitus 8 endocrinologydiseases
osteoporosis 9 endocrinologydiseases
raloxifene 3 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Teriparatide 17011 decreases [[]]; therefore, agents that are capable of increasing BMD may be useful in preventing fractures. Teriparatide , the only current agent used to promote bone formation, decreased the bone PEN content and increased
Teriparatide 17166 bone formation, decreased the bone PEN content and increased BMD in a non-diabetic animal model [[]]. Teriparatide may be useful as a treatment for osteoporosis in diabetic patients because it could improve the bone
raloxifene 16282 material properties of bone. In the subanalysis of the MORE study, which examined the preventive effect of raloxifene on vertebral fracture in postmenopausal osteoporotic women, the risk of vertebral fracture after the
raloxifene 16580 subgroup [[]]. When a non-diabetic animal with elevated PEN induced by experimental diet was treated with raloxifene , bone strength recovered, presumably by decreasing the bone PEN content [[]]. Therefore, raloxifene
raloxifene 16680 raloxifene, bone strength recovered, presumably by decreasing the bone PEN content [[]]. Therefore, raloxifene administration to diabetic patients is expected to improve the material properties of the bone matrix
Select Disease Character Offset Disease Term Instance
diabetes mellitus 1227 pathogenesis of this unique clinical manifestation through physical and biological mechanisms in patients with diabetes mellitus .IntroductionDiabetic patients have a higher fracture risk than expected by their bone mineral density
diabetes mellitus 2326 residues on proteins, lipids, and nucleic acids. Growing evidence of fracture risk in patients with diabetes mellitus indicates the crucial roles of AGEs in aggravating bone fragility, as in the cases of the progression
diabetes mellitus 3377 on the BMD values of diabetic patients. Diabetes mellitus is classified into two major types: type 1 diabetes mellitus (T1DM), which is caused by a loss of the ability to secrete insulin that possesses an anabolic action
diabetes mellitus 3517 caused by a loss of the ability to secrete insulin that possesses an anabolic action on bone, and type 2 diabetes mellitus (T2DM), which develops in the presence of underlying insulin resistance. In T1DM, BMD measured in the
diabetes mellitus 5617 although their BMD was higher than the control group [[], []]. Taken together, these findings suggest that diabetes mellitus is an underlying disease that causes secondary osteoporosis because the risk of fracture is increased
diabetes mellitus 10216 PEN concentrations were related to an increased risk of fractures in patients with type 1 and type 2 diabetes mellitus [[]–[], []•] (Table 1). These associations are independent of BMD. Therefore, the bone fragility
diabetes mellitus 15395 receptor for advanced glycation end products (esRAGE) and vertebral fractures in patients with type 2 diabetes mellitus . The data are expressed as odds ratios of vertebral fracture after adjusting for age, body mass index,
diabetes mellitus 17930 fracture in the diabetic patients with decreased BMD.ConclusionsThe bone fragility in patients with diabetes mellitus is predominantly caused by poor bone quality because BMD is not always a useful estimate of the bone
osteoporosis 2899 dual-energy X-ray absorptiometry (DXA), and the fracture rate was observed in postmenopausal women with osteoporosis . In 1991, osteoporosis was defined as “a disease that is characterized by low bone mass, microarchitectural
osteoporosis 2922 absorptiometry (DXA), and the fracture rate was observed in postmenopausal women with osteoporosis. In 1991, osteoporosis was defined as “a disease that is characterized by low bone mass, microarchitectural deterioration
osteoporosis 3169 enhanced bone fragility, and consequent increase in fracture risk” [[]], and the diagnostic criteria for osteoporosis , which were primarily based on BMD, were established. In contrast, there was less information on the
osteoporosis 5682 together, these findings suggest that diabetes mellitus is an underlying disease that causes secondary osteoporosis because the risk of fracture is increased in diabetic patients, irrespective of their diabetic clinical
osteoporosis 15845 glycation end products. *P < 0.05; **P < 0.01. Adapted from ref. [[]]Therapeutic Effects of Anti- osteoporosis Agents on Diabetic PatientA few clinical studies showed that some anti-osteoporosis agent drugs potentially
osteoporosis 15929 Effects of Anti-osteoporosis Agents on Diabetic PatientA few clinical studies showed that some anti- osteoporosis agent drugs potentially prevent fractures in diabetic patients. When considering the pathological state
osteoporosis 16049 drugs potentially prevent fractures in diabetic patients. When considering the pathological state of osteoporosis in diabetic patients, bone fragility in patients with diabetes may be rescued by improving the bone
osteoporosis 17212 and increased BMD in a non-diabetic animal model [[]]. Teriparatide may be useful as a treatment for osteoporosis in diabetic patients because it could improve the bone matrix quality by reversing the impaired bone
osteoporosis 18439 fragility would provide unique diagnostic criteria and treatment strategies for this specific form of osteoporosis
type 1 diabetes mellitus 3370 information on the BMD values of diabetic patients. Diabetes mellitus is classified into two major types: type 1 diabetes mellitus (T1DM), which is caused by a loss of the ability to secrete insulin that possesses an anabolic action
type 2 diabetes mellitus 3510 is caused by a loss of the ability to secrete insulin that possesses an anabolic action on bone, and type 2 diabetes mellitus (T2DM), which develops in the presence of underlying insulin resistance. In T1DM, BMD measured in the
type 2 diabetes mellitus 10209 urinary PEN concentrations were related to an increased risk of fractures in patients with type 1 and type 2 diabetes mellitus [[]–[], []•] (Table 1). These associations are independent of BMD. Therefore, the bone fragility
type 2 diabetes mellitus 15388 secretory receptor for advanced glycation end products (esRAGE) and vertebral fractures in patients with type 2 diabetes mellitus . The data are expressed as odds ratios of vertebral fracture after adjusting for age, body mass index,

You must be authorized to submit a review.